High‑risk, high‑reward stocks are companies whose share prices can witness large swings, either up or down, as their future is uncertain. However, they have the potential to deliver explosive gains in a short window. Analysts are pointing to three such names with meaningful catalysts ahead: Wave Life Sciences (WVE), Verastem (VSTM), and Real Brokerage (REAX).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Let’s take a closer look at the three stocks:
- Wave Life Sciences (WVE)
Wave Life Sciences is a closely watched small-cap biotech stock thanks to its next‑generation RNA-editing and gene-editing platform. The company said its editing tech is built to give more exact and longer-lasting effects than older methods. Wave also has deals with big drugmakers, which gives it funding help and possible future milestone payments.
The upside depends on success in human trials, but analysts say that even early proof that Wave’s platform works could trigger a share price gain.
Turning to Wall Street, Wave Life Sciences stock has a Strong Buy consensus rating based on 16 Buys assigned in the last three months. The average WVE stock price target of $24 implies upside potential of 276.5%.
- Verastem (VSTM)
Verastem is in focus due to its late-stage cancer program aimed at RAS‑mutated tumors, one of the hardest areas in cancer care. Its lead drug has shown early, hopeful signs in combo studies, and analysts expect key trial updates later this year. If the data stays strong, Verastem could draw buyout interest or move faster toward regulatory approvals.
Wall Street’s consensus rating for VSTM stock is Strong Buy based on seven unanimous Buys. The average analyst price target of $16.00 implies an upside potential of 277.36% from current levels.
- Real Brokerage (REAX)
Real Brokerage is one of the fastest-growing tech-driven real estate firms in North America, using a low-cost, cloud model to bring in agents and grow its share of the market. The company has been adding agents fast, closing more deals, and slowly improving its profit numbers.
Analysts see Real as a high-beta play on a housing rebound and the shift of agents toward digital platforms. If the company keeps growing at this pace and lifts its margins, the stock could move much higher.
On TipRanks, analysts have a Strong Buy consensus rating on REAX stock based on four Buys assigned in the past three months. Further, the average Real Brokerage price target of $4.92 per share implies 176.22% upside potential.
